{"id":70390,"date":"2026-07-22T11:12:03","date_gmt":"2026-07-22T03:12:03","guid":{"rendered":"https:\/\/flcube.com\/?p=70390"},"modified":"2026-07-22T11:12:05","modified_gmt":"2026-07-22T03:12:05","slug":"nanjing-delova-biotech-completes-83m-series-c-financing-to-advance-late-stage-pain-management-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70390","title":{"rendered":"Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Nanjing Delova Biotech Co., Ltd.<\/strong> announced the completion of its <strong>Series C equity financing<\/strong> of approximately <strong>RMB 600 million<\/strong> (\u2248 <strong>US$83 million<\/strong>). The round was <strong>co-led<\/strong> by <strong>Govtor Capital<\/strong>, <strong>Efund Capital<\/strong>, <strong>Riverhead Capital<\/strong>, and <strong>Oriza Holdings<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-funding-details\" class=\"wp-block-heading\">Funding Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Amount Raised<\/strong><\/td><td>RMB 600 million (\u2248 US$83 million)<\/td><\/tr><tr><td><strong>Round<\/strong><\/td><td>Series C<\/td><\/tr><tr><td><strong>Lead Investors<\/strong><\/td><td>Govtor Capital, Efund Capital, Riverhead Capital, Oriza Holdings<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Clinical development of three late-stage pipeline candidates, indication expansion, IND filings for small-molecule pipelines<\/td><\/tr><tr><td><strong>Company Focus<\/strong><\/td><td>Non-addictive novel drugs in pain management<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-portfolio-amp-regulatory-milestones\" class=\"wp-block-heading\">Product Portfolio &amp; Regulatory Milestones<\/h2>\n\n\n\n<h3 id=\"h-qamzova-meloxicam\" class=\"wp-block-heading\">Qamzova (Meloxicam)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Status:<\/strong> Approved for marketing in <strong>China<\/strong> and <strong>United States<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First <strong>24-hour long-acting NSAID injection<\/strong> in China<\/li>\n\n\n\n<li><strong>Regulatory Achievement:<\/strong> First <strong>Chinese novel analgesic drug<\/strong> to receive <strong>FDA marketing approval<\/strong><\/li>\n\n\n\n<li><strong>Special Recognition:<\/strong> Among very few domestic innovative drugs to receive <strong>FDA &#8220;Application Fee Waivers&#8221;<\/strong> support<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-qp-6211\" class=\"wp-block-heading\">QP-6211<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Status:<\/strong> <strong>NDA accepted<\/strong> by China&#8217;s <strong>NMPA<\/strong> in <strong>December 2025<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> World&#8217;s first <strong>long-acting ropivacaine injection<\/strong> with positive <strong>Phase III<\/strong> results from two clinical trials<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Next-generation amide local anesthetic with superior pain targeting and excellent cardiac\/CNS safety<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-company-profile\" class=\"wp-block-heading\">Company Profile<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Founded in <strong>2017<\/strong>, Delova Biotech specializes in developing <strong>non-addictive novel therapeutics<\/strong> for pain management\u2014a critical focus area given global concerns about opioid dependency. The company has successfully transitioned from early-stage research to commercial-stage operations with multiple approved and near-term approvable products.<\/p>\n\n\n\n<h2 id=\"h-strategic-outlook\" class=\"wp-block-heading\">Strategic Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Series C funding positions Delova to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Accelerate <strong>late-stage clinical development<\/strong> across three pipeline candidates<\/li>\n\n\n\n<li>Expand <strong>indications<\/strong> for existing approved products<\/li>\n\n\n\n<li>Advance <strong>globally competitive small-molecule pipelines<\/strong> based on innovative targets through IND filings<\/li>\n\n\n\n<li>Strengthen <strong>global regulatory strategy<\/strong> leveraging existing FDA approval precedent<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Delova Biotech Co., Ltd. announced the completion of its Series C equity financing of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70395,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[],"class_list":["post-70390","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Delova Biotech Co., Ltd. announced the completion of its Series C equity financing of approximately RMB 600 million (\u2248 US$83 million). The round was co-led by Govtor Capital, Efund Capital, Riverhead Capital, and Oriza Holdings.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70390\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline\" \/>\n<meta property=\"og:description\" content=\"Nanjing Delova Biotech Co., Ltd. announced the completion of its Series C equity financing of approximately RMB 600 million (\u2248 US$83 million). The round was co-led by Govtor Capital, Efund Capital, Riverhead Capital, and Oriza Holdings.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70390\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-22T03:12:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-22T03:12:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2201.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70390#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70390\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline\",\"datePublished\":\"2026-07-22T03:12:03+00:00\",\"dateModified\":\"2026-07-22T03:12:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70390\"},\"wordCount\":311,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70390#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2201.webp\",\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70390#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70390\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70390\",\"name\":\"Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70390#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70390#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2201.webp\",\"datePublished\":\"2026-07-22T03:12:03+00:00\",\"dateModified\":\"2026-07-22T03:12:05+00:00\",\"description\":\"Nanjing Delova Biotech Co., Ltd. announced the completion of its Series C equity financing of approximately RMB 600 million (\u2248 US$83 million). The round was co-led by Govtor Capital, Efund Capital, Riverhead Capital, and Oriza Holdings.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70390#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70390\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70390#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2201.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2201.webp\",\"width\":1080,\"height\":608,\"caption\":\"Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70390#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Delova Biotech Co., Ltd. announced the completion of its Series C equity financing of approximately RMB 600 million (\u2248 US$83 million). The round was co-led by Govtor Capital, Efund Capital, Riverhead Capital, and Oriza Holdings.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70390","og_locale":"en_US","og_type":"article","og_title":"Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline","og_description":"Nanjing Delova Biotech Co., Ltd. announced the completion of its Series C equity financing of approximately RMB 600 million (\u2248 US$83 million). The round was co-led by Govtor Capital, Efund Capital, Riverhead Capital, and Oriza Holdings.","og_url":"https:\/\/flcube.com\/?p=70390","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-22T03:12:03+00:00","article_modified_time":"2026-07-22T03:12:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2201.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70390#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70390"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline","datePublished":"2026-07-22T03:12:03+00:00","dateModified":"2026-07-22T03:12:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70390"},"wordCount":311,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70390#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2201.webp","articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70390#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70390","url":"https:\/\/flcube.com\/?p=70390","name":"Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70390#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70390#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2201.webp","datePublished":"2026-07-22T03:12:03+00:00","dateModified":"2026-07-22T03:12:05+00:00","description":"Nanjing Delova Biotech Co., Ltd. announced the completion of its Series C equity financing of approximately RMB 600 million (\u2248 US$83 million). The round was co-led by Govtor Capital, Efund Capital, Riverhead Capital, and Oriza Holdings.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70390#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70390"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70390#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2201.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2201.webp","width":1080,"height":608,"caption":"Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70390#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2201.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70390"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70390\/revisions"}],"predecessor-version":[{"id":70396,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70390\/revisions\/70396"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70395"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}